<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The recent approval of Biogen Inc’s (NASDAQ: BIIB) high-price Alzheimer’s drug is raising questions about who will have access to the $56,000/year treatment that could cost Medicare billions of dollars in coming years. Medicare typically pays unconditionally for approved medicines, but to limit the financial hit from Aduhelm, however, Medicare could restrict access, the Wall Street Journal reported.
...read full article on Benzinga
